Daily Sepsis Research Analysis
Three papers stood out today: a mechanistic Immunity study revealing a bladder–blood immune barrier that restrains uropathogen dissemination (with implications for preventing urosepsis), a Lancet Digital Health cohort showing time-series deep learning can accurately predict bloodstream infections ahead of culture results, and an Advanced Science preclinical theranostic DNA-origami platform enabling early detection and targeted therapy in sepsis-associated acute kidney injury.
Summary
Three papers stood out today: a mechanistic Immunity study revealing a bladder–blood immune barrier that restrains uropathogen dissemination (with implications for preventing urosepsis), a Lancet Digital Health cohort showing time-series deep learning can accurately predict bloodstream infections ahead of culture results, and an Advanced Science preclinical theranostic DNA-origami platform enabling early detection and targeted therapy in sepsis-associated acute kidney injury.
Research Themes
- Innate immune barrier mechanisms preventing urosepsis
- AI-driven early diagnosis of bloodstream infections
- Nanomedicine theranostics in sepsis-associated organ injury
Selected Articles
1. A bladder-blood immune barrier constituted by suburothelial perivascular macrophages restrains uropathogen dissemination.
This mechanistic study identifies suburothelial perivascular macrophages as a bladder–blood immune barrier that captures UPEC, maintains vascular integrity, and deploys METosis with MMP-13 to trap bacteria and recruit neutrophils. Monocyte-derived replenishment confers protection against recurrent UTIs, suggesting new strategies to prevent urosepsis.
Impact: Revealing a tissue-resident immune barrier that restrains systemic bacterial dissemination challenges and advances current understanding of UTI-to-urosepsis transition. It opens targetable pathways (METosis, MMP-13, macrophage training) for prevention.
Clinical Implications: While preclinical, the findings suggest avenues to prevent urosepsis by enhancing suPVM function, modulating METosis/MMP-13, or leveraging monocyte training/vaccination to bolster bladder barrier immunity.
Key Findings
- Identified suburothelial perivascular macrophages (suPVMs) that capture UPEC and preserve inflamed vessel integrity during acute cystitis.
- suPVMs undergo METosis to release macrophage extracellular DNA traps into the urothelium, sequestering bacteria and releasing MMP-13 to promote neutrophil transuroepithelial migration.
- Monocyte-derived replenishment of suPVMs after prior infection confers protection against recurrent UTIs, constituting a bladder–blood immune barrier that restrains dissemination.
Methodological Strengths
- Rigorous in vivo mechanistic mapping across infection phases with functional readouts (capture, vessel integrity, METosis).
- Integration of cellular dynamics (monocyte replenishment) with effector pathways (MMP-13, neutrophil migration).
Limitations
- Preclinical murine models; human validation is needed.
- Pathogen breadth and strain-specificity beyond UPEC require testing.
Future Directions: Validate suPVM signatures and METosis/MMP-13 pathways in human bladder tissue; test pharmacologic or vaccine strategies to enhance barrier function and reduce urosepsis.
Urinary tract infections (UTIs) predominantly occur in the bladder and can potentially progress into life-threatening sepsis if uropathogens spread unconstrainedly into the bloodstream. Here, we identified a subset of suburothelial perivascular macrophages (suPVMs) in the bladder that exerted a pivotal barrier function to prevent systemic bacterial dissemination during acute cystitis. During the initial phase of uropathogenic Escherichia coli (UPEC) infection, suPVMs actively captured UPEC invading the laminal propria and maintained the integrity of inflamed vessels. They subsequently underwent METosis to expel macrophage extracellular DNA traps (METs) into the urothelium to sequester bacteria within this avascular compartment. Matrix metallopeptidase-13 was released along with METs to promote neutrophil transuroepithelial migration. Replenished suPVMs from monocytes following a prior infection were functionally competent to confer protection against recurrent UTIs. Our study thus uncovers a bladder-blood immune barrier in restraining uropathogen dissemination, which could have implications for the prevention and treatment of urosepsis.
2. Utilising routinely collected clinical data through time series deep learning to improve identification of bacterial bloodstream infections: a retrospective cohort study.
Using 20,850 admissions, an LSTM model leveraging 14-day longitudinal labs predicted pathogenic bloodstream infections with AUROC 0.97 in a temporal hold-out set, outperforming static models. Temporal dynamics of CRP, eosinophils, and platelets were key features, suggesting feasibility for earlier, individualized decision-making.
Impact: Demonstrates clinically actionable performance for early BSI prediction using routinely collected data, with strong potential to improve diagnostic stewardship and reduce unnecessary antibiotics.
Clinical Implications: Integrating time-series predictive models into sepsis workups could triage high-risk patients for expedited diagnostics and targeted therapy, while curbing empiric antibiotic use in low-risk cases.
Key Findings
- LSTM using up to 14 days of prior labs achieved AUROC 0.97 and AUPRC 0.65 in a temporal hold-out test set, outperforming static logistic models (AUROC 0.74).
- Time-series information was critical, especially for hospital-acquired bloodstream infections; removing temporal dynamics degraded performance.
- CRP, eosinophil, and platelet trajectories were consistently important predictors of culture outcomes.
Methodological Strengths
- Large single-system cohort with temporal hold-out validation and cross-validation in training.
- Direct comparison of time-series deep learning versus static baselines with interpretable feature importance.
Limitations
- Single health system; external multi-center prospective validation is needed.
- Outcome labeling depends on culture classification (pathogen vs contamination), which may introduce misclassification.
Future Directions: Prospective impact studies integrating the model into clinical workflows, assessment of clinician-in-the-loop strategies, and external validation across diverse settings.
BACKGROUND: Blood cultures are the gold standard for diagnosing bacterial bloodstream infections, but test results are only available 24-48 h after sampling. We aimed to develop and evaluate models using health-care data to predict bloodstream infections in patients admitted to hospital. METHODS: In this retrospective cohort study, we used routinely collected blood biomarkers and demographic data from patients who underwent blood sample collection for testing via culture between March 3, 2014, and Dec 1, 2021, at Imperial College Healthcare NHS Trust (London, UK) as model features. Data up to 14 days before blood sample collection were provided to long short-term memory (LSTM) or static logistic regression models. The primary outcome was prediction of blood culture results, defined as a pathogenic bloodstream infection (ie, isolation of pathogenic bacteria of interest) or no bloodstream infection (ie, no growth or contamination). Data collected up to Feb 28, 2021 (n=15 212) comprised the training set and were evaluated against a temporal hold-out test set comprising patients who were sampled after March 1, 2021 (n=5638). FINDINGS: Among 20 850 patients with available data, pathogenic bacteria were observed in the cultured blood samples of 3866 (18·5%) patients. 2920 (62·2%) of 4897 patients who had their blood samples taken more than 48 h after admission to hospital had pathogenic bloodstream infections, and so were defined as having hospital-acquired bloodstream infections. Including data from the 7 days before admission (7-day window approach) and using five-fold cross validation in the training set gave an area under receiver operator curve (AUROC) of 0·75 (IQR 0·68-0·82) and an area under the precision recall curve (AUPRC) of 0·58 (0·46-0·77) for static models and an AUROC of 0·92 (0·91-0·93) and AUPRC of 0·75 (0·72-0·76) for the LSTM model. In the hold-out test set performances were: AUROC of 0·74 (95% CI 0·70-0·78) and AUPRC of 0·48 (0·43-0·53) for static models and AUROC of 0·97 (0·96-0·97) and AUPRC of 0·65 (0·60-0·70) for LSTM. Removal of time series information resulted in lower model performance, particularly for hospital-acquired bloodstream infections. Dynamics of C-reactive protein concentration, eosinophil count, and platelet count were important features for prediction of blood culture results. INTERPRETATION: Deep learning models accounting for longitudinal changes could support individualised clinical decision making for patients at risk of bloodstream infections. Appropriate implementation into existing diagnostic pathways could enhance diagnostic stewardship and reduce unnecessary antimicrobial prescribing. FUNDING: UK Department of Health and Social Care, the National Institute for Health and Care Research, and the Wellcome Trust.
3. A Dual-Response DNA Origami Platform for Imaging and Treatment of Sepsis-Associated Acute Kidney Injury.
A DNA origami theranostic platform responds to elevated miR-21 in SA-AKI, enabling dual fluorescence and photoacoustic imaging while scavenging ROS and delivering LL-37 for antimicrobial activity. In preclinical models, the integrated approach improved survival by 80%, showcasing precision nanomedicine for sepsis-related organ injury.
Impact: Introduces a programmable nanoplatform that unites early detection and targeted therapy in SA-AKI, a major contributor to sepsis morbidity and mortality.
Clinical Implications: If translated, such theranostics could enable earlier identification of SA-AKI and timely antimicrobial/antioxidant interventions, potentially improving outcomes beyond current supportive care.
Key Findings
- miR-21-triggered strand displacement in DNA origami restores Cy5 fluorescence, enabling real-time SA-AKI detection with dual fluorescence and photoacoustic imaging.
- DNA origami exhibits ROS-scavenging properties and, when conjugated with LL-37, provides bactericidal activity.
- Theranostic integration improved survival by 80% in SA-AKI preclinical models.
Methodological Strengths
- Rational biomarker-triggered sensing (miR-21) coupled with orthogonal imaging readouts.
- Therapeutic convergence (ROS scavenging + antimicrobial peptide) with survival benefit in vivo.
Limitations
- Preclinical models; human pharmacokinetics, biodistribution, and safety remain unknown.
- Complex manufacturing and regulatory pathways for DNA nanostructures.
Future Directions: Scale up GMP-compatible manufacturing, evaluate safety/tox in large animals, and design early-phase trials for high-risk sepsis populations with emerging AKI.
Current diagnostics for sepsis-associated acute kidney injury (SA-AKI) detect kidney damage only at advanced stages, limiting opportunities for timely intervention. A DNA origami-based nanoplatform is developed for the early diagnosis and treatment of SA-AKI. Modified with a fluorophore (Cy5) and quencher (BHQ3), the DNA origami remains nonfluorescent under normal conditions. During SA-AKI, elevated microRNA-21 triggers a strand displacement reaction that restores the fluorescence signal, enabling real-time detection. Additionally, the photoacoustic changes of BHQ3, driven by different excretion rates of the nanostructure and released DNA strands, enable dual-mode imaging, enhancing diagnostic accuracy. Therapeutically, DNA origami scavenges reactive oxygen species and, when conjugated with the antimicrobial peptide Leucine-Leucine-37 (LL-37), exhibits bactericidal effects. This combination boosts survival rates by 80% in SA-AKI models. This dual-response nanoplatform integrates precise imaging and targeted therapy, offering a powerful strategy for SA-AKI management and advancing applications of DNA origami in precision nanomedicine.